November 23, 2015
Pfizer and Allergan in $160B merger
Pfizer and Allergan have entered into a definitive merger agreement under which Pfizer will combine with Allergan in a transaction valued at about $160 billion.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 23, 2015
Pfizer’s ex man joins Vertex as Vice President and Chief Legal Officer
Vertex Pharmaceuticals, a biotechnology company has appointed Pfizer’s Senior Vice president Michael J. Parini to the role of Executive Vice President and Chief Legal Officer.
November 23, 2015
Diplomat to distribute myeloma drug Ninlaro
Diplomat Pharmacy reported on Monday that it is a member of a limited panel of specialty pharmacies selected to distribute Ninlaro as a treatment for patients with relapsed and/or refractory multiple myeloma.
November 23, 2015
India’s Aurobindo gets USFDA’s OK for its pulmonary tablets ‘Sildenafil’
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil…
November 23, 2015
Akers aims to launch new products. Appoints new CEO
A medical device company Akers Biosciences has appointed John J. Gormally as Chief Executive Officer from the global medical technology company Becton Dickinson
November 23, 2015
Green light in EU for Novartis’ Cosentyx
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
November 23, 2015
Geistlich Pharma recalls Decalcit chewing tablets due to Italian version typo
The Swiss-based company Geistlich Pharma AG is recalling batch of Decalcit, vitamin D and calcium chewable tablets, from the market.
November 20, 2015
Johnson Johnson’s Biosense Webster buys medical device company Coherex Medical
Biosense Webster has acquired Coherex Medical, Inc. a privately held medical device company based in Salt Lake City, Utah.
November 20, 2015
Janssen applies to FDA New Drug Application for Invokamet XR
Janssen Research & Development, LLC has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Invokamet extended release (XR).
November 20, 2015
Bayer submits its new five-year-contraceptive for EU and US marketing Authorization
Bayer has submitted an application for marketing authorization in both the European Union and in the United States for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system